Form 4: West Pharmaceutical Services VP & Treasurer Reports Stock Transactions
SEC Form 4 Filing
Charles Witherspoon, VP & Treasurer of West Pharmaceutical Services, reports acquisition and disposal of common stock and stock options.
Summary
- Charles Witherspoon, VP & Treasurer of West Pharmaceutical Services Inc. (WST), filed a Form 4 detailing changes in beneficial ownership.
- On February 18, 2025, Witherspoon acquired 65.706 shares of common stock at $211 through the exercise of options.
- On the same day, Witherspoon disposed of 23.492 shares of common stock at $211 to cover tax obligations.
- Following these transactions, Witherspoon directly owns 1,295.355 shares of common stock.
- Witherspoon also acquired 548 stock options with an exercise price of $211, exercisable beginning February 18, 2026, and expiring on February 18, 2035.
- Additionally, Witherspoon acquired 237 restricted stock units (RSUs) that vest in four equal installments beginning on February 18, 2026.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Future Outlook
The stock options and restricted stock units vest over time, incentivizing the reporting person to contribute to the company's long-term success.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Stock option grants and RSU awards are common compensation practices in the pharmaceutical industry, used to align management's interests with those of shareholders.
- The vesting schedules and exercise prices are typical for such awards, designed to incentivize long-term performance.
- Comparing the size of the grants to those of peers at companies like Catalent, Inc. and Lonza Group AG would provide further context on the magnitude of the compensation.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine compensation practices.
- Employees may be indirectly affected by the incentive structure created by the stock options and RSUs.
Key Dates
| Date | Description |
|---|---|
| 02/18/2025 | Date of earliest transaction: Acquisition and disposal of common stock, and acquisition of stock options and restricted stock units. |
| 02/18/2026 | First vesting date for stock options and restricted stock units. |
| 02/18/2035 | Expiration date for stock options. |
| 02/20/2025 | Date of signature for the report. |
Keywords
Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, WST, West Pharmaceutical Services, Charles Witherspoon, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.